{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:24:17Z","timestamp":1789680257360,"version":"4.0.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021771","name":"Student Research Committee, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["63765"],"award-info":[{"award-number":["63765"]}],"id":[{"id":"10.13039\/501100021771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.euf.2021.08.011","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T20:13:50Z","timestamp":1632341630000},"page":"1072-1089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-1771","authenticated-orcid":false,"given":"Hadi","family":"Mostafaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Salehi-Pourmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Jilch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta Lisa","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico C.","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Schuettfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmajeed","family":"Aydh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sari Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus G.","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakineh","family":"Hajebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2021.08.011_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2021.08.011_bib0010","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.juro.2010.10.048","article-title":"The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey","volume":"185","author":"Link","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000343536","article-title":"Sex differences in the physiology and pharmacology of the lower urinary tract","volume":"6","author":"Patra","year":"2013","journal-title":"Curr Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0020","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.urology.2013.12.027","article-title":"Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?","volume":"83","author":"Herschorn","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.08.011_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1590\/S1677-5538.IBJU.2013.05.08","article-title":"Idiopathic and neurogenic detrusor overactivity: do the different patterns have urodynamic characteristics related to gender or neurological condition?","volume":"39","author":"Valentini","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-149-3-200808050-00005","article-title":"Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial","volume":"149","author":"Burgio","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2021.08.011_bib0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","article-title":"Clinical guidelines for overactive bladder","volume":"16","author":"Yamaguchi","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0040","first-page":"373","article-title":"[EAU guidelines on urinary incontinence]","volume":"35","author":"Thuroff","year":"2011","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euf.2021.08.011_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.euf.2021.08.011_bib0050","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","article-title":"Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence","volume":"19","author":"Andersson","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0055","first-page":"2061","article-title":"Newer agents for the management of overactive bladder","volume":"74","author":"Epstein","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.euf.2021.08.011_bib0060","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1464-410X.2006.06677.x","article-title":"Overactive bladder syndrome in older people","volume":"99","author":"Wagg","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0065","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","article-title":"Managing overactive bladder","volume":"22","author":"Robinson","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.euf.2021.08.011_bib0070","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.euf.2021.08.011_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.euf.2021.08.011_bib0080","series-title":"Network meta-analysis using frequentist methods","author":"Rucker","year":"2017"},{"key":"10.1016\/j.euf.2021.08.011_bib0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.euf.2021.08.011_bib0090","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016718","article-title":"Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach","volume":"6","author":"Kessler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2021.08.011_bib0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","article-title":"Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis","volume":"69","author":"Vouri","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.euf.2021.08.011_bib0105","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","volume":"4","author":"Nabi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2021.08.011_bib0110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1248\/bpb.30.54","article-title":"Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents","volume":"30","author":"Ohtake","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.euf.2021.08.011_bib0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00192-011-1411-6","article-title":"Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity","volume":"22","author":"Glavind","year":"2011","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2021.08.011_bib0125","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1464-410X.2007.07358.x","article-title":"Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo","volume":"101","author":"Ney","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2021.08.011_bib0140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1464-410X.2005.05296.x","article-title":"Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged & or = 50 years","volume":"95","author":"Diefenbach","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2165\/00044011-200626100-00007","article-title":"Psychotic disorder induced by oxybutynin: presentation of two cases","volume":"26","author":"Gulsun","year":"2006","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.euf.2021.08.011_bib0150","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4111\/kju.2013.54.12.806","article-title":"Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects","volume":"54","author":"Cetinel","year":"2013","journal-title":"Korean J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2020.10.010","article-title":"Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis","author":"Mostafaei","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2021.08.011_bib0160","article-title":"Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis","author":"Mostafaei","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2021.08.011_bib0165","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0170","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-2042.2006.01387.x","article-title":"Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome","volume":"13","author":"Abrams","year":"2006","journal-title":"International J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0180","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/nau.22945","article-title":"Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study","volume":"36","author":"Amarenco","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2021.08.011_bib0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/nau.23281","article-title":"Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study","volume":"37","author":"Bray","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2021.08.011_bib0190","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00044011-200019020-00001","article-title":"Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms","volume":"19","author":"Chancellor","year":"2000","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.euf.2021.08.011_bib0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double\u2010blind placebo\u2010and tolterodine\u2010controlled trial of the once\u2010daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0205","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.juro.2013.08.082","article-title":"Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome","volume":"191","author":"Chapple","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/luts.12152","article-title":"Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment","volume":"10","author":"Chua","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2021.08.011_bib0220","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.curtheres.2009.11.001","article-title":"Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder","volume":"70","author":"Chu","year":"2009","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.euf.2021.08.011_bib0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urology.2007.11.008","article-title":"Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study","volume":"71","author":"Dmochowski","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.08.011_bib0230","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2009.09.018","article-title":"Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder","volume":"75","author":"Dmochowski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.08.011_bib0235","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.euf.2021.08.011_bib0240","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.juro.2013.08.027","article-title":"Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial","volume":"191","author":"Dubeau","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0245","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2010.03.147","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder","volume":"184","author":"Frenkl","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0250","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.12174","article-title":"Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder","volume":"112","author":"Ginsberg","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0255","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-2042.2011.02732.x","article-title":"Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial","volume":"18","author":"Gotoh","year":"2011","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0260","first-page":"A146","article-title":"Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial","volume":"21","author":"Hajebrahimi","year":"2014","journal-title":"International J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0265","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0270","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1185\/03007990802537122","article-title":"Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms","volume":"24","author":"Herschorn","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euf.2021.08.011_bib0275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","article-title":"Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head\u2010to\u2010head placebo\u2010controlled trial","volume":"105","author":"Herschorn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0280","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1464-410X.2003.04468.x","article-title":"Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial","volume":"92","author":"Homma","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0285","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1442-2042.2008.02104.x","article-title":"A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0290","first-page":"499","volume":"16","author":"Homma","year":"2009","journal-title":"A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. International J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0295","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0301-2115(00)00561-3","article-title":"Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder","volume":"98","author":"Jacquetin","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.euf.2021.08.011_bib0300","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000096338","article-title":"Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder","volume":"77","author":"Junemann","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0305","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1464-410X.2010.09640.x","article-title":"Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial","volume":"107","author":"Kaplan","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urology.2008.08.485","article-title":"Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Karram","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.08.011_bib0315","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0320","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2021.08.011_bib0325","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1464-410X.2009.09050.x","article-title":"Urinary urgency outcomes after propiverine treatment for an overactive bladder: the\u2019 Propiverine study on overactive bladder including urgency data\u2019","volume":"105","author":"Lee","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0330","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-410X.2009.08361.x","article-title":"Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study","volume":"103","author":"Malone-Lee","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.20928","article-title":"Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder","volume":"30","author":"Marencak","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2021.08.011_bib0340","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","article-title":"Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity","volume":"161","author":"Millard","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0345","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0350","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2006.06146.x","article-title":"Efficacy and tolerability of tolterodine extended\u2010release in continent patients with overactive bladder and nocturia","volume":"97","author":"Nitti","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0355","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0360","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cct.2014.04.009","article-title":"Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial","volume":"38","author":"Orri","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euf.2021.08.011_bib0365","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00192-008-0688-6","article-title":"Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women","volume":"19","author":"Rogers","year":"2008","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.euf.2021.08.011_bib0370","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/nau.23852","article-title":"Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study","volume":"38","author":"Shin","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2021.08.011_bib0375","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ijcp.12540","article-title":"The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study","volume":"69","author":"Song","year":"2015","journal-title":"Int J Clin Pract"},{"issue":"3 Pt 1","key":"10.1016\/j.euf.2021.08.011_bib0380","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.juro.2007.05.058","article-title":"Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial","volume":"178","author":"Staskin","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0385","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00192-002-1009-0","article-title":"A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder","volume":"14","author":"Swift","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.euf.2021.08.011_bib0390","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.08.011_bib0395","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jgs.12088","article-title":"Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial","volume":"61","author":"Wagg","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2021.08.011_bib0400","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","article-title":"Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder","volume":"100","author":"Yamaguchi","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0405","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1757-5672.2011.00091.x","article-title":"Efficacy, safety and tolerability of fesoterodine in Asian patients with overactive bladder","volume":"3","author":"Yamaguchi","year":"2011","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2021.08.011_bib0410","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.08.011_bib0415","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective \u03b23\u2010adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double\u2010blind, placebo\u2010controlled, dose\u2010finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2021.08.011_bib0420","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"issue":"6 Part 1","key":"10.1016\/j.euf.2021.08.011_bib0425","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.08.011_bib0430","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00345-005-0507-3","article-title":"Efficacy and tolerability of darifenacin, a muscarinic M 3 selective receptor antagonist (M 3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder","volume":"23","author":"Zinner","year":"2005","journal-title":"World J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921002261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921002261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:52:55Z","timestamp":1762498375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456921002261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2405456921002261"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2021.08.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2021.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}